Amylyx Pharmaceuticals Future Growth
Future criteria checks 0/6
Amylyx Pharmaceuticals is forecast to grow earnings and revenue by 29.5% and 77.5% per annum respectively. EPS is expected to grow by 34.2% per annum. Return on equity is forecast to be -26.5% in 3 years.
Key information
29.5%
Earnings growth rate
34.17%
EPS growth rate
| Pharmaceuticals earnings growth | 14.4% |
| Revenue growth rate | 77.5% |
| Future return on equity | -26.48% |
| Analyst coverage | Good |
| Last updated | 19 Dec 2025 |
Recent future growth updates
Recent updates
Amylyx Faced With Big Rally Reality Check: Why I Choose To Hold
Oct 08Here's Why We're A Bit Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Situation
Sep 01
Can Amylyx Pharmaceuticals (NASDAQ:AMLX) Afford To Invest In Growth?
May 10Optimistic Investors Push Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Up 26% But Growth Is Lacking
Apr 03
Avexitide Launch In 2027 Will Strengthen Our Pipeline
Strategic developments in the pipeline and collaborations aim to address unmet medical needs and present long-term revenue growth opportunities.Amylyx Pharmaceuticals: Lots Of Setbacks, Some Chances Of Recovery
Feb 24Little Excitement Around Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Revenues As Shares Take 26% Pounding
Dec 19Is Amylyx Pharmaceuticals (NASDAQ:AMLX) In A Good Position To Invest In Growth?
Dec 10Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along
Nov 25There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise
Nov 04Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry
Sep 18Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
Jun 25Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop
Apr 25Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically
Mar 12An ALS Drug Fails Again
Mar 09Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications
Feb 23Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues
Feb 23Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper
Nov 10Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Sep 24Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 34 | -158 | -151 | N/A | 8 |
| 12/31/2026 | N/A | -146 | -141 | N/A | 9 |
| 12/31/2025 | N/A | -148 | -146 | N/A | 9 |
| 9/30/2025 | -1 | -149 | -155 | -154 | N/A |
| 6/30/2025 | 0 | -188 | -202 | -166 | N/A |
| 3/31/2025 | -1 | -219 | -243 | -207 | N/A |
| 12/31/2024 | 87 | -302 | -204 | -168 | N/A |
| 9/30/2024 | 196 | -259 | -132 | -95 | N/A |
| 6/30/2024 | 299 | -166 | -60 | -59 | N/A |
| 3/31/2024 | 398 | -71 | 15 | 17 | N/A |
| 12/31/2023 | 381 | 49 | 11 | 12 | N/A |
| 9/30/2023 | 294 | 2 | -53 | -51 | N/A |
| 6/30/2023 | 192 | -73 | -91 | -89 | N/A |
| 3/31/2023 | 94 | -149 | -147 | -144 | N/A |
| 12/31/2022 | 22 | -198 | -182 | -180 | N/A |
| 9/30/2022 | 0 | -184 | -161 | -158 | N/A |
| 6/30/2022 | 0 | -153 | -138 | -136 | N/A |
| 3/31/2022 | 0 | -121 | -103 | -103 | N/A |
| 12/31/2021 | 0 | -88 | -75 | -75 | N/A |
| 9/30/2021 | 1 | -68 | -56 | -55 | N/A |
| 12/31/2020 | 1 | -42 | -37 | -37 | N/A |
| 12/31/2019 | 1 | -14 | -11 | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMLX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AMLX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AMLX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AMLX is forecast to have no revenue next year.
High Growth Revenue: AMLX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AMLX is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/26 19:39 |
| End of Day Share Price | 2025/12/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amylyx Pharmaceuticals, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christopher Chen | Baird |
| null null | Baird |
| Joel Beatty | Baird |